Division of Johnson & Johnson
Latest From LifeScan Inc.
Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.
Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market
The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Medtech M&A activity waned in June, with the market showing signs of a summer slump. Twelve acquisitions were announced and closed during the month, a dip in activity compared to the 21 deals recorded in the same period last year, and the 17 recorded in May.
In Vitro Diagnostics
- Glucose Testing
- Monitoring Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
- Val Asbury, Worldwide Pres.
- Contact Info
Phone: (800) 227-8862
965 Chesterbrook Blvd.
Wayne, PA 19087
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.